Segment Information

3 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Segment Information

12. Segment Information

Segment revenue, operating (loss) income, and depreciation and amortization were as follows:

	Three Months Ended
	December 31,
(In thousands)	2021			2020
Revenue:
Medical Device	$	16,908		$	16,196
In Vitro Diagnostics		6,095			6,101
Total revenue	$	23,003		$	22,297
Operating (loss) income:
Medical Device	$	(3,792	)	$	(593	)
In Vitro Diagnostics		3,155			3,220
Total segment operating (loss) income		(637	)		2,627
Corporate		(2,804	)		(2,534	)
Total operating (loss) income	$	(3,441	)	$	93
Depreciation and amortization:
Medical Device	$	2,194		$	1,652
In Vitro Diagnostics		86			105
Corporate		96			103
Total depreciation and amortization	$	2,376		$	1,860

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.